Amy Raskin's Latest Portfolio Moves: Ascendis Pharma, Automation, and Cybersecurity

New Investment in Ascendis Pharma

• 💡 Amy Raskin has initiated a new buy in Ascendis Pharma, a Danish biotech company.
• 🎯 Ascendis Pharma has reached profitability and has a technology that extends the half-life of drugs, potentially improving efficacy and safety.
• 🚀 The company has two drugs on the market, another one coming, and the potential to license its core technology.

Overweighting Healthcare Sector

• 📈 Raskin has been discussing healthcare for a while and remains overweight in the healthcare sector.
• ⚠️ While still liking Nera, a small trim was made to fund some of the Ascendis Pharma purchase.

Adding to Automation and Tech Stocks

• 🤖 Fanuc, Cognex, and Impinj are identified as key automation plays.
• 📌 Impinj, which focuses on ultra-high frequency RFID, is being added to after a recent pullback, despite its volatility.
• 💻 Cognex is recognized as a long-term leader in Vision Technologies with a $6 billion market cap.
• ⚡ CrowdStrike, a leader in cybersecurity, saw a recent dip in its stock price, presenting an opportunity for adding to the position.
• 🛢️ AIA and SLB are mentioned in the context of the energy sector, which has been underinvested.